Strengthening global partnerships for a cancer-free future 🌍, @icmr_nicpr joins hands with University of Oklahoma’s Stephenson Cancer Center @StephensonCC to advance affordable and accessible solutions for #CervicalCancer
A significant step toward #CervicalCancerElimination.
Congratulations to Dr. Sanghamitra Pati, Additional Director General, @ICMRDELHI , on being conferred the prestigious FNASc honour. A proud moment celebrating excellence in scientific research.
ICMR-NICPR, in collaboration with UCMS & GTB Hospital, has launched a community-based #cervical#cancer#screening program in Delhi, using the WHO-recommended HPV DNA test
Funded by @ICMRDELHI, the initiative aims to enhance early detection & improve community health
#WeAreICMR
What turns a research idea into a national impact? 💭
DG, ICMR explains the 4Ds behind ICMR’s Extramural Grants —
✨ Discovery
⚙️ Development
🚚 Delivery
📊 Descriptive
Together, they power the journey from Lab → Life. 🔬➡️❤️
#WeAreICMR#ResearchThatMatters
Empowering #cervical#cancer#prevention in India! 🇮🇳
ICMR-NICPR inaugurates a state-of-the-art High Throughput HPV DNA Testing Laboratory, designed to deliver affordable, high-quality HPV testing across the country—strengthening early detection and saving lives.
#WeAreICMR
#ICMR Organizes ICMR-SHINE Initiative – Science & Health Innovation for the Nextgen Explorers – a Nationwide Student Outreach Program
Around 13,000 students from grades 9–12, representing over 300 schools across 39 districts in 16 states and union territories, participated in a variety of interactive activities. These included guided laboratory tours, research exhibitions, poster walks, video presentations, and live demonstrations showcasing ongoing scientific work. Watch the report by @Nitendradd@ICMRDELHI@MoHFW_INDIA@jpnadda
#ISHTA2025 | Union Health & Family Welfare and Chemicals & Fertilizers Minister Shri @JPNadda to inaugurate the International Symposium on Health Technology Assessment (ISHTA) 2025 today at 10:00 AM at Bharat Mandapam, New Delhi.
With the theme “Bridging Evidence to Policy: Health Technology Assessment for Affordable Healthcare,” the symposium will bring together global experts, policymakers & innovators to promote evidence-based health policies & cost-effective innovations.
Join the conversation & watch live: https://t.co/X7thtuqiCk
Our scientist @dr_showket delivered a lecture & chaired a technical session on "next-Gen #Cancer#Biology & emerging infectious diseases" during the National Conference on Sustainable Biotech Solutions for Global challenges, Feb 19 -21 at Jamai Hamdard University, New Delhi
Exciting first day of our DHR-ICMR sponsored “Hands-on Training in #HPV-DNA #Diagnostics” with a guest lecture by our eminent speaker Prof. (Dr.) Col. Shakhar Kashyap, sharing invaluable insights on impact & use of tobacco on cardiovascular disease and cancer.
#CancerResearch
Dr. Showket Hussain was invited to deliver a lecture on “Harnessing genomic landscape for clinical relevance among Indian #breastcancer patients” at 1st J&K International Conference on Breast Cancer & Awareness, at University of Kashmir in collaboration with SERB-DST
Honoured to be visited by Dr VM Katoch, Former Secretary DHR & DG ICMR & Dr Kiran Katoch Former Director NJIL&OMD Agra.
They shared their insights & appreciation about the good work being carried out at @ICMR_NJILOMD Agra and @NICPR_Noida.
We wish them a healthy life ahead.
📣 Registation now open for the DHR sponsored training program on #HPV#DNA#Diagnostics from August 5 to 9, 2024.
Interested candidates may register using the link below 👇🏽
https://t.co/oTuwNgMlp2
@drshalini_icmr
AIIMS starts Validation Study of Indigenous HPV Tests for Cervical Cancer Screening
Worldwide, cervical cancer is the fourth most common cancer in women, causing one death every two minutes. In India, it is the second most common cancer in women. According to GLOBOCAN 2022, an estimated 663,301 women were diagnosed with cervical cancer worldwide and about 348,874 women died from the disease. In India, there are approximately 127,526 new cases and 79,906 deaths per annum. Cervical cancer is preventable and can be treated if detected in precancerous or early stages. Persistent infection with high-risk human papilloma virus (HPV) has been found to be the necessary cause of cervical cancer.
India is committed to achieve a cervical cancer free world, as envisaged by the World Health Organisation. For this, we need to screen 70% of women (35-45 years) and vaccinate 90% of girls against HPV by 2030.
Presently, HPV tests are expensive and need elaborate laboratory set ups, therefore, there is an urgent need to develop and validate low-cost, point of care indigenous HPV tests, which can detect the major cancer-causing HPV genotypes in the Indian population.
With this vision, this multi-centre study has been started with the support of DBT-BIRAC Grand Challenges India in collaboration with WHO’s International Agency for Research in Cancer (IARC). The testing will be performed at AIIMS, New Delhi, NICPR Noida and NIRRCH Mumbai.
Director AIIMS Dr. Srinivas inaugurated the programme in a hybrid meeting at Dr. BRAIRCH in the presence of IRCH Chief Prof Sushma Bhatnagar, Dean Research Prof. JS Titiyal, Mission Director Grand Challenges India Birac Dr. Shirshendu Mukherjee and study investigators Prof Neerja Bhatla, Dr Shalini Singh, Dr Seema Singhal, Dr Pranay Tanwar, Dr Showket Hussain, Dr Anushree Patil, Dr Vikrant Bhor and others.
This landmark project will allow validation of Make in India HPV tests for cervical cancer screening by international quality standards and will benefit millions of women in India and other LMICs to get rid of the scourge of cervical cancer.
Dr Rajiv Bahl, DG @ICMRDELHI & Secretary @DeptHealthRes interacted with our scientists.
We had a great interactive session covering ongoing work and future plans.
Our scientists greatly benefited with his insights and vision.
@drshalini_icmr